Recent Advances in the Pharmacology of Tardive Dyskinesia

키워드

참고문헌 (126)

1. Cunningham Owens DG, "A guide to the extrapyramidal side-effects of antipsychotic drugs" (2014), Cambridge University Press
2. Factor SA, "Drug induced movement disorders" (2005), USA Blackwell Publishing
3. Waln O, "An update on tardive dyskinesia: from phenomenology to treatment", Tremor Other Hyperkinet Mov (N Y), 3 (2013)
4. Caroff SN, "Drug-induced extrapyramidal syndromes : implications for contemporary practice", Psychiatr Clin North Am, 39, pp.391~411 (2016)
5. Carbon M, "Tardive dyskinesia prevalence in the period of second-generation antipsychotic use : a meta-analysis", J Clin Psychiatry, 78, pp.e264~e278 (2017)
6. Carbon M, "Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials : a meta-analysis", World Psychiatry, 17, pp.330~340 (2018)
7. Woods SW, "Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study", J Clin Psychiatry, 71, pp.463~474 (2010)
8. Factor SA, "Recent developments in drug-induced movement disorders : a mixed picture", Lancet Neurol, 18, pp.880~890 (2019)
9. Stegmayer K, "Tardive dyskinesia associated with atypical antipsychotics : prevalence, mechanisms and management strategies", CNS Drugs, 32, pp.135~147 (2018)
10. Achalia RM, "Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia", Asian J Psychiatr, 9, pp.31~35 (2014)
11. Ryu S, "Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics : a cross-sectional and retrospective study", J Clin Psychopharmacol, 35, pp.13~21 (2015)
12. Caroff SN, "Cumulative burden of illness in veterans with tardive dyskinesia and serious mental disorders", J Clin Psychopharmacol, 40, pp.38~45 (2020)
13. Caroff SN, "RE-KINECT : a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings", J Clin Psychopharmacol, 40, pp.259~268 (2020)
14. Caroff SN, "Historical perspectives on tardive dyskinesia", J Neurol Sci, 389, pp.4~9 (2018)
15. Caroff SN, "Awareness and impact of possible tar-dive dyskinesia by primary psychiatric diagnosis in patients prescribed antipsychotics: results from the RE-KINECT study", Academy of Managed Care Pharmacy (AMCP)Nexus 2018 (2018)
16. Caroff SN, "A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia", J Clin Psychiatry, 81, pp.19cs12983~ (2020)
17. Caroff SN, "Overcoming barriers to effective management of tardive dyskinesia", Neuropsychiatr Dis Treat, 15, pp.785~794 (2019)
18. Caroff SN, "Pharmacological treatment of tardive dyskinesia : recent developments", Expert Rev Neurother, 17, pp.871~881 (2017)
19. Caroff SN, "Correlates of the abnormal involuntary movement scale in veterans with tardive dyskinesia", J Clin Psychopharmacol, 40, pp.373~380 (2020)
20. Kane JM, "Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia assessment workshop", J Clin Psychiatry, 79, pp.17cs11959~ (2018)
21. Jeste DV, "Tardive dyskinesia and neuroleptics: from dogma to reason", pp.15~32 (1986), American Psychiatric Press
22. Margolese HC, "Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction", Can J Psychiatry, 50, pp.541~547 (2005)
23. Teo JT, "Tardive dyskinesia is caused by maladaptive synaptic plasticity : a hypothesis", Mov Disord, 27, pp.1205~1215 (2012)
24. Loonen AJ, "New insights into the mechanism of drug-induced dyskinesia", CNS Spectr, 18, pp.15~20 (2013)
25. Hyde TM, "Drug induced movement disorders", pp.213~256 (2005), Blackwell Publishing
26. Witter DP, "Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients", Expert Opin Pharmacother, 18, pp.965~972 (2017)
27. Bhidayasiri R, "Evidence-based guideline : treatment of tardive syndromes : report of the guideline development subcommittee of the American Academy of Neurology", Neurology, 81, pp.463~469 (2013)
28. Bhidayasiri R, "Updating the recommendations for treatment of tardive syndromes : a systematic review of new evidence and practical treatment algorithm", J Neurol Sci, 389, pp.67~75 (2018)
29. Soares-Weiser K, "Tardive dyskinesia", Semin Neurol, 27, pp.159~169 (2007)
30. Soares-Weiser K, "Miscellaneous treatments for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 3, pp.CD000208~ (2018)
31. Margolius A, "Current treatment of tardive dyskinesia", Parkinsonism Relat Disord, 59, pp.155~160 (2019)
32. Lehman AF, "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
33. Meyer JM, "Future directions in tardive dyskinesia research", J Neurol Sci, 389, pp.76~80 (2018)
34. Seeman P, "Psychosis pathways converge via D2high dopamine receptors", Synapse, 60, pp.319~346 (2006)
35. Kostrzewa RM, "Lifelong rodent model of tardive dyskinesia-persistence after antipsychotic drug withdrawal", Curr Top Behav Neurosci, 29, pp.353~362 (2016)
36. Moore KE, "Dyskinesia : animal experimental correlates", Acta Psychiatr Scand, 63(291 Suppl), pp.88~102 (1981)
37. Klawans HL Jr, "The pharmacology of tardive dyskinesias", Am J Psychiatry, 130, pp.82~86 (1973)
38. D’Abreu A, "Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review", Tremor Other Hyperkinet Mov(N Y), 8, pp.570~ (2018)
39. Hernandez G, "Tardive dyskinesia is associated with altered putamen Akt", GSK-3β signaling in nonhuman primates, 2019, pp.34, 717~726
40. Mahmoudi S, "Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model", Mov Disord, 29, pp.1125~1133 (2014)
41. Jiang LH, "One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists", J Pharmacol Exp Ther, 253, pp.1198~1205 (1990)
42. Soares KV, "The treatment of tardive dyskinesia--a systematic review and meta-analysis", Schizophr Res, 39, pp.1~16 (1999)
43. El-Sayeh HG, "Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 1, pp.CD000458~ (2018)
44. Chan CH, "Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia : a 24-week follow-up study", Int Clin Psychopharmacol, 33, pp.155~162 (2018)
45. Mentzel CL, "Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness : the Curaçao extrapyramidal syndromes study XII", J Clin Psychiatry, 78, pp.e279~e285 (2017)
46. Lin CC, "Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia", J Neurol Sci, 389, pp.48~54 (2018)
47. Caroff SN, "Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia", J Clin Psychiatry, 72, pp.295~303 (2011)
48. Fernandez HH, "The course of tardive dyskinesia and parkinsonism in psychiatric inpatients : 14-year follow-up", Neurology, 56, pp.805~807 (2001)
49. Turek I, "Tardive dyskinesia : its relation to neuroleptic and antiparkinson drugs", Br J Psychiatry, 121, pp.605~612 (1972)
50. Kane JM, "Tardive dyskinesia : prevalence, incidence, and risk factors", J Clin Psychopharmacol, 8(4 Suppl), pp.52S~56S (1988)
51. Gilbert PL, "Neuroleptic withdrawal in schizophrenic patients. A review of the literature", Arch Gen Psychiatry, 52, pp.173~188 (1995)
52. Bergman H, "Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia", Health Technol Assess, 21, pp.1~218 (2017)
53. Casey DE, "Tardive dyskinesia and neuroleptics: from dogma to reason", pp.76~97 (1986), American Psychiatric Press
54. Glazer WM, "A discontinuation study", Arch Gen Psychiatry, 41, pp.623~627 (1984)
55. Zutshi D, "Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic", Tremor Other Hyperkinet Mov (N Y), 4, pp.266~ (2014)
56. Bergman H, "Antipsychotic reduction and", or cessation and antipsychotics as specific treatments for tardive dyskinesia, 2018, pp.2, CD000459~
57. Quitkin F, "Tardive dyskinesia:are first signs reversible?", Am J Psychiatry, 134, pp.84~87 (1977)
58. Jeste DV, "Tardive dyskinesia--reversible and persistent", Arch Gen Psychiatry, 36, pp.585~590 (1979)
59. Kane JM, "Tardive dyskinesia : a task force report of the American Psychiatric Association" (1992), American Psychiatric Association
60. Kane JM, "Tardive dyskinesia and neuroleptics: from dogma to reason", pp.100~107 (1986), American Psychiatric Press
61. Caroff SN, "Hospital utilization rates following antipsychotic dose reductions : implications for tardive dyskinesia", BMC Psychiatry, 18, pp.306~ (2018)
62. Caroff SN, "Hospital utilization rates following antipsychotic dose reduction in mood disorders : implications for treatment of tardive dyskinesia", BMC Psychiatry, 20, pp.365~ (2020)
63. Egan MF, "Treatment of tardive dyskinesia", Schizophr Bull, 23, pp.583~609 (1997)
64. Kazamatsuri H, "Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine", Am J Psychiatry, 130, pp.479~483 (1973)
65. Mentzel TQ, "Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia : a meta-analysis", J Clin Psychiatry, 79, pp.17r11852~ (2018)
66. Tarsy D, "Effects of newer antipsychotics on extrapyramidal function", CNS Drugs, 16, pp.23~45 (2002)
67. Tenback DE, "Effects of antipsychotic treatment on tardive dyskinesia : a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes(SOHO)study", J Clin Psychiatry, 66, pp.1130~1133 (2005)
68. Jankovic J, "Dopamine depleters in the treatment of hyperkinetic movement disorders", Expert Opin Pharmacother, 17, pp.2461~2470 (2016)
69. Citrome L, "Tardive dyskinesia : placing vesicular monoamine transporter type 2(VMAT2)inhibitors into clinical perspective", Expert Rev Neurother, 18, pp.323~332 (2018)
70. Meyer JM, "Forgotten but not gone : new developments in the understanding and treatment of tardive dyskinesia", CNS Spectr, 21(1 Suppl), pp.13~24 (2016)
71. Scorr LM, "VMAT2 inhibitors for the treatment of tardive dyskinesia", J Neurol Sci, 389, pp.43~47 (2018)
72. Solmi M, "Treatment of tardive dyskinesia with VMAT-2 inhibitors : a systematic review and meta-analysis of randomized controlled trials", Drug Des Devel Ther, 12, pp.1215~1238 (2018)
73. Caroff SN, "Treatment of tardive dyskinesia with tetrabenazine or valbenazine : a systematic review", J Comp Eff Res, 7, pp.135~148 (2018)
74. Leung JG, "Tetrabenazine for the treatment of tardive dyskinesia", Ann Pharmacother, 45, pp.525~531 (2011)
75. Citrome L, "Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?", Int J Clin Pract, 71, pp.e12964~ (2017)
76. O’Brien CF, "NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia : a randomized, double-blind, placebo-controlled study", Mov Disord, 30, pp.1681~1687 (2015)
77. Hauser RA, "KINECT 3 : a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia", Am J Psychiatry, 174, pp.476~484 (2017)
78. Factor SA, "The effects of valbenazine in participants with tardive dyskinesia : results of the 1-year KINECT 3 extension study", J Clin Psychiatry, 78, pp.1344~1350 (2017)
79. Caroff S, "Characteristics of patients with tardive dyskinesia who maintain treatment response after discontinuing long-term valbenazine: pooled analysis of two trials", ACNP 57th Annual Meeting (2018)
80. Citrome L, "Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?", Int J Clin Pract, 71, pp.e13030~ (2017)
81. Fernandez HH, "Randomized controlled trial of deutetrabenazine for tardive dyskinesia : the ARM-TD study", Neurology, 88, pp.2003~2010 (2017)
82. Anderson KE, "Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia(AIM-TD) : a double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Psychiatry, 4, pp.595~604 (2017)
83. Anderson KE, "Deutetrabenazine for the treatment of tardive dyskinesia: results from an open-label, long-term study", American Psychiatric Association (APA) 2017 Annual Meeting (2017)
84. Mandel RJ, "A quantitative estimate of the role of striatal D-2 receptor proliferation in dopaminergic behavioral supersensitivity : the contribution of mesolimbic dopamine to the magnitude of 6-OHDA lesion-induced agonist sensitivity in the rat", Behav Brain Res, 59, pp.53~64 (1993)
85. Moy SS, "Differential effects of bilateral dopamine depletion in neonatal and adult rats", Neurosci Biobehav Rev, 21, pp.425~435 (1997)
86. Borgkvist A, "Synaptic plasticity may underlie l-DOPA induced dyskinesia", Curr Opin Neurobiol, 48, pp.71~78 (2018)
87. Stanley N. Caroff, "Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors", Clinical Psychopharmacology and Neuroscience, 18(2), pp.322~326 (2020), 대한정신약물학회[DOI]
88. Gunne LM, "An animal model for coexisting tardive dyskinesia and tardive parkinsonism : a glutamate hypothesis for tardive dyskinesia", Clin Neuropharmacol, 16, pp.90~95 (1993)
89. Andreassen OA, "Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats", Br J Pharmacol, 119, pp.751~757 (1996)
90. Oertel W, "Randomized, placebo-controlled trial of ADS-5102(amantadine)extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease(EASE LID 3)", Mov Disord, 32, pp.1701~1709 (2017)
91. Paik J, "Amantadine extended-release(GOCOVRITM) : a review in levodopa-induced dyskinesia in Parkinson’s disease", CNS Drugs, 32, pp.797~806 (2018)
92. Caroff SN, "Revisiting amantadine as a treatment for drug-induced movement disorders", Ann Clin Psychiatry, 32, pp.198~208 (2020)
93. Kornhuber J, "Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties", J Neural Transm, 43(Suppl), pp.91~104 (1994)
94. Greenamyre JT, "N-methyl-D-aspartate antagonists in the treatment of Parkinson’s disease", Arch Neurol, 48, pp.977~981 (1991)
95. Stoof JC, "The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acidevoked release of acetylcholine from rat neostriatum in a non-competitive way", Eur J Pharmacol, 213, pp.439~443 (1992)
96. Perez-Lloret S, "Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia", J Neural Transm(Vienna), 125, pp.1237~1250 (2018)
97. Vale S, "Amantadine for dyskinesia tarda", N Engl J Med, 284, pp.673~ (1971)
98. Allen RM, "Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration", Biol Psychiatry, 17, pp.719~727 (1982)
99. Crane GE, "More on amantadine in tardive dyskinesia", N Engl J Med, 285, pp.1150~1151 (1971)
100. Angus S, "A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia", J Clin Psychopharmacol, 17, pp.88~91 (1997)
101. Pappa S, "Effects of amantadine on tardive dyskinesia : a randomized, double-blind, placebo-controlled study", Clin Neuropharmacol, 33, pp.271~275 (2010)
102. van Harten PN, "The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia : the Curaçao extrapyramidal syndromes study II", Schizophr Res, 26, pp.235~242 (1997)
103. Ward KM, "Antipsychotic-related movement disorders:drug-induced parkinsonism vs. tardive dyskinesiakey differences in pathophysiology and clinical management", Neurol Ther, 7, pp.233~248 (2018)
104. Miller R, "Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia", Biol Psychiatry, 34, pp.713~738 (1993)
105. Conti MM, "A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia", Neurosci Biobehav Rev, 92, pp.67~82 (2018)
106. Bergman H, "Anticholinergic medication for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 1, pp.CD000204~ (2018)
107. Caroff SN, "Treatment of tardive dyskinesia with donepezil : a pilot study", J Clin Psychiatry, 62, pp.772~775 (2001)
108. Caroff SN, "Treatment of tardive dyskinesia with galantamine : a randomized controlled crossover trial", J Clin Psychiatry, 68, pp.410~415 (2007)
109. Tammenmaa-Aho I, "Cholinergic medication for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 3, pp.CD000207~ (2018)
110. Shen W, "M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia", Neuron, 88, pp.762~773 (2015)
111. Quik M, "Potential therapeutic application for nicotinic receptor drugs in movement disorders", Nicotine Tob Res, 21, pp.357~369 (2019)
112. Bonsi P, "Centrality of striatal cholinergic transmission in Basal Ganglia function", Front Neuroanat, 5, pp.6~ (2011)
113. Chambers NE, "Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat", Neuroscience, 409, pp.180~194 (2019)
114. Bordia T, "Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum", J Pharmacol Exp Ther, 342, pp.327~334 (2012)
115. Quik M, "Nicotine and nicotinic receptor drugs : potential for Parkinson’s disease and drug-induced movement disorders", Int Rev Neurobiol, 124, pp.247~271 (2015)
116. Bordia T, "Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats", J Pharmacol Exp Ther, 340, pp.612~619 (2012)
117. Stanley N. Caroff, "Effect of Varenicline on Tardive Dyskinesia: A Pilot Study", Clinical Psychopharmacology and Neuroscience, 19(2), pp.355~360 (2021), 대한정신약물학회[DOI]
118. Alabed S, "Gammaaminobutyric acid agonists for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 4, pp.CD000203~ (2018)
119. Bergman H, "Benzodiazepines for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 1, pp.CD000205~ (2018)
120. Woods SW, "Effects of levetiracetam on tardive dyskinesia : a randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 69, pp.546~554 (2008)
121. Lister J, "Lipoic acid and haloperidol-induced vacuous chewing movements : Implications for prophylactic antioxidant use in tardive dyskinesia", Prog Neuropsychopharmacol Biol Psychiatry, 72, pp.23~29 (2017)
122. Adelufosi AO, "Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia", Cochrane Database Syst Rev, (4), pp.CD010501~ (2015)
123. Zheng W, "Extract of Ginkgo biloba for tardive dyskinesia : metaanalysis of randomized controlled trials", Pharmacopsychiatry, 49, pp.107~111 (2016)
124. Soares-Weiser K, "Vitamin E for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 1, pp.CD000209~ (2018)
125. Hatcher-Martin JM, "Propranolol therapy for tardive dyskinesia : a retrospective examination", Parkinsonism Relat Disord, 32, pp.124~126 (2016)
126. Salem H, "Revisiting antipsychotic-induced akathisia : current issues and prospective challenges", Curr Neuropharmacol, 15, pp.789~798 (2017)

관련 논문AI추천